Myocardial Infarction Treatment Market - Global Industry Analysis

Market Overview     

The global Myocardial Infarction Treatment market accounted for USD 1553 Million in 2020 and is expected to reach USD 2246.10 Million by 2028, growing at a CAGR of around 4.6% between 2021 and 2028.

Growing cases of cardiovascular ailments and sedentary life patterns will impact the expansion of the myocardial infarct treatment market within the years ahead. Besides this, factors like obesity, diabetes, smoking habits, hypertension, low physical activity, and diabetes are anticipated to impact the expansion of the myocardial infarct treatment market within the near future. Escalating drug costs alongside growing expenditure on clinical trials are probably going to hamper the expansion of the myocardial infarct treatment market within the coming years.

Furthermore, rising costs of R& D programs alongside strict legislation governing the treatment can obstruct the business growth within the ensuing years. Nonetheless, mounting adoption of innovative treatment methods across developing nations will boost the industry revenue, thereby normalizing the impact of hindrances on the myocardial infarct treatment market, reports the myocardial infarct treatment market study.

COVID-19 Impact Analysis  

Besides, the COVID-19 outbreak, there's a drastic rise in the demand for healthcare facilities across the world. 2020 has been a dramatic rush of ICU visits and checkups so far, all because of a pandemic that has shaken the entire world. The Novel Coronavirus that caused the COVID-19 disease unleashed a disaster of extraordinary proportions. As healthcare spends for COVID-19 increases exponentially, companies that conduct research, develop potential vaccines, produce test kits, and manufacture or supply medical equipment are likely to benefit the most. The reason is clear - governments across the world will invest in not only damage control, but also in the prevention of any potential resurgence of the pandemic. This also means that companies other than those manufacturing PPE or infrastructure support that is not directly connected to COVID-19 would face disruptions in business.

Growth Factors

Globally, the increasing incidence of arteria coronaria disease and changes in lifestyle, an increasing number of smokers, increasing incidence of obesity, and lack of exercise are the prime growth drivers of the worldwide myocardial infarct Treatment market. Additionally, an increase in the adoption of myocardial infarct Treatment in emerging economies like China, India among others, will create new opportunities for the global myocardial infarct Treatment market. However, the upper cost of research and development, and limited R&D Activities are the key restraints for the global myocardial infarct Treatment market.

Report Scope:  

Segment Analysis Preview  

Based on product type the market is segmented into antiplatelet agents, glycoprotein IIb/IIIa inhibitors, antithrombotic agents, beta-adrenergic blockers, vasodilators, angiotensin-converting enzyme (ace) inhibitors, angiotensin-receptor blockers, analgesics, thrombolytics. Key distribution channels covered under this study include hospitals, hospital pharmacies, drug stores, and online drug stores. 

Based on distribution channels, hospitals and hospital pharmacies both have accounted for the major market share in 2018 due to the increased investments in healthcare infrastructure & the use of advanced technologies. However, online drug stores are expected to witness the fastest growth within the forecast period due to increasing demand from healthcare participants in surgical care such as; healthcare professionals, patients, and insurers. Additionally, increasing demand for patient satisfaction, cost-effective procedures, and efficient practices by healthcare professionals also are expected to spice up the expansion of this market within the forecast period.

Regional Analysis Preview

Regionally, North America has been leading the worldwide myocardial infarct treatment market and is anticipated to continue on the dominant position within the years to return. The rise in the geriatric population base and growing cases of heart ailments is that the main factor behind the dominance of the North American myocardial infarct treatment market. The high number of market players being headquartered in North America is another significant factor that's supporting this regional myocardial infarct treatment market.

Key Market Players & Competitive Landscape

The major players that are comprised in  Myocardial Infarction Treatment market are Bayer, Novartis, Daiichi Sankyo Company Limited, Boehringer Ingelheim GmbH, Sandoz, Astrazeneca, Janssen Biotech, Inc., Merck & Co. Inc., Sanofi, Pfizer Inc. among others.

The global  Myocardial Infarction Treatment Market is segmented as follows:

By Product Type

• Antiplatelet agents
• Glycoprotein IIb/IIIa inhibitors
• Antithrombotic agents
• Beta-adrenergic blockers
• Vasodilators
• Angiotensin-Converting Enzyme (ACE) inhibitors
• Angiotensin-Receptor blockers
• Analgesics
• Thrombolytics

By Distribution Channel

• Hospitals
• Hospital Pharmacies
• Drug Stores
• Online Drug Stores

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa